User profiles for Tom Wilkinson

Tom Wilkinson

University of Southampton
Verified email at soton.ac.uk
Cited by 15568

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

…, R Lambkin-Williams, T Wilkinson… - Proceedings of the …, 2010 - National Acad Sciences
RNA interference (RNAi) is a natural mechanism regulating protein expression that is
mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human …

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease

TMA Wilkinson, GC Donaldson, JR Hurst… - American journal of …, 2004 - atsjournals.org
Treatment of chronic obstructive pulmonary disease (COPD) exacerbations improves
outcomes; however, responses to treatment are variable, and patients with COPD often delay …

[HTML][HTML] Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

TM Wilkinson, CKF Li, CSC Chui, AKY Huang… - Nature medicine, 2012 - nature.com
Protective immunity against influenza virus infection is mediated by neutralizing antibodies,
but the precise role of T cells in human influenza immunity is uncertain. We conducted …

[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

…, E Smith, C Hopkins, N Noulin, B Löndt, T Wilkinson… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has caused hundreds of millions of cases and continues to circulate globally. To establish …

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 …

…, T Clark, R Djukanovic, TMA Wilkinson… - The Lancet …, 2021 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries
a substantial risk of severe and prolonged illness; treatment options are currently limited. …

Airway and systemic inflammation and decline in lung function in patients with COPD

…, TAR Seemungal, IS Patel, A Bhowmik, TMA Wilkinson… - Chest, 2005 - Elsevier
Study objectives Patients with COPD experience lower airway and systemic inflammation,
and an accelerated decline in FEV 1 . There is no evidence on whether this inflammation …

Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease

…, WR Perera, TMA Wilkinson… - American journal of …, 2006 - atsjournals.org
Impact: This study explores the use of measuring plasma biomarkers at exacerbation of
chronic obstructive pulmonary disease (COPD), providing insight into the underlying …

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

TAR Seemungal, TMA Wilkinson, JR Hurst… - American journal of …, 2008 - atsjournals.org
Rationale: Frequent chronic obstructive pulmonary disease (COPD) exacerbations are a
major cause of hospital admission and mortality and are associated with increased airway …

Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2

TM Wilkinson, PHH Sykes, B Simcock… - American journal of …, 2015 - Elsevier
Objective Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 in
women younger than 25 years may reduce overtreatment. However, long-term efficacy …

[HTML][HTML] Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor.

BH Chung, T Wilkinson, JC Geer, JP Segrest - Journal of lipid research, 1980 - Elsevier
A rapid method has been developed for separation of the major plasma lipoproteins from up
to 96 ml of plasma by a single ultracentrifugation step. This separation was achieved by a …